KUBO Group Engaged to Construct Advanced World Class Cannabis Production Facility in New South Wales, Australia
MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF) (the “Company” or “MYM”) is pleased to announce that Puf Ventures Australia (the “Company”) has engaged renowned Dutch greenhouse builder, KUBO for, engineering and tender process for the construction of the 1,200,000 sqft fully automated greenhouse to be built in New South Wales Australia, the Northern Rivers Project.
The Company has chosen renowned Dutch greenhouse builder KUBO, to engineer and tender the first Ultra-Clima Greenhouse in Australia specifically for Cannabis. With the Ultra-Clima, KUBO Group has made advancements towards the greenhouse of the future. The Ultra-Clima greenhouse meets all the requirements of modern growers, higher yields, maximum food safety, minimum energy and water consumption, minimum CO2 emissions and improved returns.
The Northern Rivers Project consists of multiple zones over 1,200,000 sqft. This facility is believed to be the Southern Hemisphere’s largest purpose-built greenhouse, designed specifically to produce medical-grade cannabis. Upon completion, the facility will have an estimated annual production capacity of over 100,000 kg of cannabis.
The Northern Rivers greenhouse project, with the guidance of greenhouse expert and pioneer, Casey Houwelings is poised to deliver more combined automation, efficiency, good manufacturing practices and sustainability features under one roof than any other existing greenhouse in the world.
The new facility will create of 300 jobs in the Northern Rivers Region of New South Wales with opportunities for many downstream businesses in the region. The support from all levels of government as been overwhelming and we hope to repay this support with even more job creation. Northern Rivers is a partnership between MYM Nutraceuticals and PUF VENTURES Canada (CSE:PUF) of which MYM owns 35%.
To clarify the news release issued on November 16, 2017, the Houwelings Group of companies has no connection to the Northern Rivers project in any manner and Casey Houwelings is acting as an independent consultant through his company, Glasshouse Holdings. Casey Houweling is providing advice on greenhouse design and construction and is not involved in the operations of the Australia project. Casey Houwelings is currently not directly overseeing operations of the Houwelings Group which rests with the executive management team of the Houwelings Group.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sqft of production space. MYM is also a partner in a 1.2 million sqft production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that recently legalized cannabis and MYM is a pioneering leader there. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF) for an Investor Presentation.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.